Towards Healthcare
HIV Drugs Market Size Expects to Surge $52.95 Bn by 2034

HIV Drugs Market Size, Share and Competitive Landscape (2025-2034)

According to forecasts, the global HIV drugs market size will grow from USD 34.75 billion in 2024 to USD 52.95 billion by 2034, with an expected CAGR of 4.3%. In 2023, combination-class drugs led the HIV drugs market with a 60% share, while hospital pharmacies dominated distribution at 50%. North America was the top region. Key players include ViiV Healthcare, Gilead, Janssen, Roche, Mylan, Theratechnologies, Boehringer Ingelheim, Cipla, Teva and Merck.

Last Updated : 01 November 2025 Category: Therapeutic Area Insight Code: 5131 Format: PDF / PPT / Excel

Content

Introduction

  • Research Objective
  • Scope of the Study
  • Definition and Taxonomy

Research Methodology

  • Research Approach
  • Data Sources
  • Assumptions

Executive Summary

  • Synopsis
  • Analyst Recommendations

Market Overview 

  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Value Chain Analysis
    • Raw Material Sourcing
    • Manufacturing Process
    • Logistics & Transportation
    • Buyer Preferences
  • Trends
    • Market Trends
    • Technological Trends
  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers
    • Bargaining Power of Buyers
    • Threat of Substitute
    • Threat of New Entrants
    • Degree of Competition
  • PESTLE Analysis for 5 Leading Countries
    • Regulatory Framework for Leading Countries/Regions
    • Supply Demand Analysis
    • Production & Consumption Statistics
    • Export Import Statistics
    • Price Trend Analysis

Global HIV Drugs Market Assessment

  • Overview
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Geography (2021 – 2033)
    • North America
    • Europe
    • Asia Pacific
    • Middle East and Africa
    • South America

North America HIV Drugs Market Assessment

  • Overview
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • North America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Europe HIV Drugs Market Assessment

  • Overview
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Europe HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Asia Pacific HIV Drugs Market Assessment

  • Overview
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Asia Pacific HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Middle East and Africa HIV Drugs Market Assessment

  • Overview
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • Middle East and Africa HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

South America HIV Drugs Market Assessment

  • Overview
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Drug Type (2021 – 2033)
    • Nucleoside Reverse Transcriptase Inhibitors (NRTIs)
    • Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
    • Protease Inhibitors (PIs)
    • Integrase Inhibitors
    • Entry and Fusion Inhibitors
    • Combination Class Drugs
  • South America HIV Drugs Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Company Profiles

  • ViiV Healthcare
    • Company Overview
    • Geographic Footprints
    • Financial Performance
    • Product Portfolio
    • SWOT Analysis
    • R&D Efforts
    • Recent Developments & Strategic Collaborations
      • Product Launch/M&A/Technical Collaboration
  • Gilead Sciences, Inc.
  • Janssen Pharmaceuticals, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Mylan Pharmaceuticals Inc.
  • Theratechnologies Inc.
  • Boehringer Ingelheim International GmbH
  • Cipla Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co., Inc.

Conclusion & Recommendations

FAQ's

Answer : Common symptoms of HIV include fever, fatigue, sore throat, and swollen lymph nodes. As the virus progresses, symptoms may worsen, including weight loss, chronic diarrhea, night sweats, and recurrent infections. It is important to note that some people may not experience any symptoms for years after being infected with HIV. Early detection through testing is crucial for timely intervention and treatment.

Answer : One significant hurdle in the HIV drug market is the development of drug resistance, where the virus mutates and becomes less susceptible to the effects of antiretroviral drugs. This resistance challenges maintaining effective treatment regimens and requires ongoing research and development efforts to stay ahead of the virus.

Answer : North America, particularly the United States, leads the market for HIV drugs due to factors such as high healthcare spending, robust research and development infrastructure, and widespread access to treatment and care services.

Answer : World Health Organization, HHS.gov., Centers for Disease Control and Prevention, HIV.gov., National Institute of Health
Any Questions

Meet the Team

Deepa Pandey is a focused and detail-oriented market research professional with growing expertise in the healthcare sector, delivering high-quality insights across therapeutic areas, diagnostics, biotechnology and healthcare services.

Learn more about Deepa Pandey

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar